pfizer inc (PFE:Stockholm)
Transactions by PFIZER INC (PFE) in the last 6 months
Pfizer Inc. (NYSE:PFE) acquired a controlling stake in Redvax GmbH from Redbiotec AG on January 5, 2015.
Pfizer Inc. (NYSE:PFE) entered into an agreement to acquire worldwide licenses of hGH-CTP from Opko Health, Inc. (NYSE:OPK) for $570 million on December 13, 2014. Under the terms of the agreement, Opko Health will receive an upfront payment of $295 million and is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. The transaction is subject ...
iTeos Therapeutics SA announced that it will receive equity funding from Pfizer Inc. on December 8, 2014.
Pfizer Inc. (NYSE:PFE) announces a share repurchase program. Under the program, the company will repurchase up to $11 billion worth of its shares. The plan will be utilized over time. The Board of Directors of Pfizer Inc. has authorized a buyback plan on October 23, 2014. On October 23, 2014, the company initiated a Market Repurchase.
Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire two commercially marketed vaccines and related production facilities from Baxter International Inc. (NYSE:BAX) for approximately $640 million on July 30, 2014. The consideration is subject to certain adjustments. The vaccine division generated a turnover of approximately €225 million ($301.86 million) recently. The transaction is subject to regulatory approvals, including some countries in the European ...
|3M Co||$164.02 USD||-1.87|
|Bayer AG||€128.07 EUR||+4.14|
|Gilead Sciences Inc||$105.54 USD||+0.40|
|Novartis AG||SFr.85.50 CHF||+1.20|
|Procter & Gamble Co/The||$90.08 USD||-1.54|
|View Industry Companies|